Oculis to Present at the 47th Annual Goldman Sachs Global Healthcare Conference

ZUG, Switzerland, June 2026 – Oculis, a global biopharmaceutical company focused on developing innovative treatments for ophthalmic and neuro-ophthalmic diseases, has announced its participation in the prestigious 47th Annual Goldman Sachs Global Healthcare Conference. The event, one of the healthcare industry's most influential investor gatherings, is being held in Miami, Florida, bringing together leading biotechnology, pharmaceutical, medical technology, and healthcare companies from around the world.

The conference serves as a major platform for healthcare organizations to share strategic updates, discuss clinical developments, highlight commercial opportunities, and engage with institutional investors. Oculis' participation underscores the company's growing presence within the global healthcare and biotechnology sectors as it continues advancing a pipeline of innovative therapies designed to address significant unmet medical needs in eye care.

Executive Leadership to Represent Oculis

During the conference, Dr. Riad Sherif, Chief Executive Officer of Oculis, is expected to participate in a fireside chat and investor discussions where he will provide insights into the company's strategic direction, clinical development programs, and long-term growth opportunities.

The presentation will offer investors and healthcare stakeholders an opportunity to gain a deeper understanding of Oculis' vision, its differentiated technology platforms, and the progress being made across its portfolio of therapeutic candidates.

Management is also expected to engage in one-on-one meetings with investors throughout the event, discussing the company's development milestones and future commercialization plans.

Importance of the Goldman Sachs Global Healthcare Conference

The Goldman Sachs Global Healthcare Conference is recognized as one of the most significant annual events in the healthcare investment community. The conference attracts executives, analysts, institutional investors, and industry experts who gather to evaluate emerging healthcare trends and investment opportunities.

Participation in this conference provides companies such as Oculis with an opportunity to:

• Present corporate and clinical updates.
• Strengthen relationships with investors.
• Highlight innovation and research achievements.
• Increase visibility within the global healthcare market.
• Discuss future growth strategies and market opportunities.

For emerging and growth-stage biotechnology companies, the conference represents an important venue for demonstrating scientific progress and business momentum.

Oculis' Mission in Ophthalmology

Oculis is dedicated to transforming the treatment landscape for patients suffering from serious ophthalmic and neuro-ophthalmic disorders. The company leverages innovative drug delivery technologies and scientific expertise to develop therapies capable of improving patient outcomes while addressing limitations associated with existing treatment approaches.

Vision-related diseases affect millions of individuals globally and remain a major cause of disability and reduced quality of life. Oculis' mission centers on delivering groundbreaking therapeutic solutions that can preserve and restore vision while enhancing patient convenience and treatment effectiveness.

Advancing a Diverse Clinical Pipeline

One of the key themes expected during Oculis' conference presentation is the advancement of its clinical pipeline. The company continues to invest heavily in research and development initiatives targeting multiple ophthalmic and neuro-ophthalmic conditions.

Its development programs focus on diseases where current treatment options remain limited or insufficient. By pursuing innovative scientific approaches, Oculis aims to create differentiated therapies capable of delivering meaningful clinical benefits.

The company's pipeline reflects a balanced strategy that combines near-term development opportunities with longer-term innovation initiatives.

Focus on Dry Eye Disease

Dry eye disease remains one of the most common ocular conditions worldwide, affecting millions of patients. Symptoms often include irritation, discomfort, blurred vision, and inflammation that can significantly impact daily life.

Oculis has been advancing therapeutic candidates designed to address underlying disease mechanisms while improving patient comfort and visual performance. The company's efforts in this area demonstrate its commitment to addressing large patient populations with significant unmet medical needs.

Investors attending the conference are expected to receive updates regarding the progress of these programs and the potential market opportunity associated with successful development.

Neuro-Ophthalmology Innovation

In addition to traditional ophthalmology indications, Oculis has expanded its focus into neuro-ophthalmology. This specialized field addresses disorders that affect the connection between the eyes and the brain.

Neuro-ophthalmic conditions can lead to vision impairment, functional limitations, and significant challenges for patients. Oculis is pursuing innovative therapeutic approaches aimed at improving outcomes for individuals living with these complex diseases.

The company's growing presence in neuro-ophthalmology highlights its commitment to exploring high-value areas of unmet medical need.

Leveraging Innovative Technology Platforms

A critical differentiator for Oculis is its emphasis on advanced technology platforms. The company has invested in proprietary technologies designed to improve drug delivery, optimize therapeutic effectiveness, and enhance patient experience.

Traditional ophthalmic treatments often face challenges related to drug absorption, administration frequency, and patient adherence. Oculis' technological innovations seek to overcome these limitations through novel delivery mechanisms and formulation strategies.

Such innovations have the potential to improve treatment outcomes while offering greater convenience for patients and healthcare providers.

Building Long-Term Shareholder Value

Participation in major investor conferences forms an important component of Oculis' broader strategy to build long-term shareholder value. Through transparent communication and consistent execution, the company seeks to demonstrate its progress toward key clinical and commercial milestones.

Investors closely monitor biotechnology companies based on several factors, including:

• Clinical trial results.
• Regulatory achievements.
• Commercial opportunities.
• Pipeline diversification.
• Financial strength.
• Strategic partnerships.

By participating in high-profile industry events, Oculis can effectively communicate its accomplishments and future plans to the investment community.

Growing Interest in Ophthalmology Markets

The global ophthalmology market continues to attract significant attention from investors due to favorable demographic trends and increasing healthcare demand. Aging populations, rising prevalence of chronic eye diseases, and advancements in biotechnology are driving substantial growth across the sector.

Innovative therapies capable of addressing unmet needs can create significant commercial opportunities. Companies that successfully develop differentiated treatments may benefit from strong market adoption and long-term revenue potential.

Oculis is positioning itself to capitalize on these opportunities through continued investment in scientific research and clinical development.

Strategic Growth Opportunities

Beyond its current pipeline, Oculis continues to evaluate opportunities for strategic growth. These may include:

• Pipeline expansion initiatives.
• Research collaborations.
• Licensing agreements.
• Commercial partnerships.
• Geographic market expansion.
• Technology platform enhancement.

Such initiatives can help strengthen the company's competitive position while accelerating the development and commercialization of innovative therapies.

Commitment to Scientific Excellence

Scientific excellence remains at the core of Oculis' corporate strategy. The company collaborates with researchers, clinicians, and healthcare professionals to ensure that its development programs are guided by rigorous scientific principles and patient-centered objectives.

Through ongoing research efforts and clinical investigations, Oculis seeks to generate high-quality evidence supporting the safety and effectiveness of its therapeutic candidates.

Investor Access to Conference Presentation

Investors who are unable to attend the Goldman Sachs Global Healthcare Conference in person may have access to webcast presentations and archived recordings through Oculis' investor relations resources, subject to availability.

Providing digital access to conference presentations enables a broader audience to stay informed about the company's latest developments and strategic priorities.

Industry Outlook and Future Expectations

The biotechnology and ophthalmology sectors continue to evolve rapidly as scientific advances create new opportunities for innovation. Companies with strong clinical pipelines, differentiated technologies, and clear strategic direction are well-positioned to benefit from these industry trends.

Oculis enters the conference at a time when investor interest in innovative healthcare companies remains strong. The company's leadership team is expected to emphasize its commitment to advancing transformative therapies while creating sustainable value for patients, healthcare providers, and shareholders.

Conclusion

Oculis' participation in the 47th Annual Goldman Sachs Global Healthcare Conference highlights the company's growing influence within the global ophthalmology and biotechnology sectors. Through executive presentations, investor meetings, and strategic discussions, Oculis will have the opportunity to showcase its clinical progress, technological innovation, and long-term growth strategy.

As the company continues advancing therapies aimed at addressing significant unmet needs in ophthalmology and neuro-ophthalmology, investors and industry stakeholders will be closely monitoring its progress. The conference represents an important milestone for Oculis as it strengthens engagement with the investment community and reinforces its commitment to delivering innovative treatments that have the potential to improve the lives of patients worldwide.

#Oculis #HealthcareConference #Biotechnology #Ophthalmology #SlimScan #GrowthStocks #CANSLIM